|
HY-P99206-1mg
|
MedChemexpress LLC
|
Naxitamab [CAS 1879925-92-4]
|
|
Cancer-programmed cell death
|
|
|
HY-P99206-10mg
|
MedChemexpress LLC
|
Naxitamab [CAS 1879925-92-4]
|
|
Cancer-programmed cell death
|
|
|
HY-P99206-5mg
|
MedChemexpress LLC
|
Naxitamab [CAS 1879925-92-4]
|
|
Cancer-programmed cell death
|
|
|
HY-P99410-1mg
|
MedChemexpress LLC
|
Ordesekimab [CAS 879293-15-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99410-10mg
|
MedChemexpress LLC
|
Ordesekimab [CAS 879293-15-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99410-5mg
|
MedChemexpress LLC
|
Ordesekimab [CAS 879293-15-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99254-1mg
|
MedChemexpress LLC
|
Racotumomab [CAS 946832-34-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99254-10mg
|
MedChemexpress LLC
|
Racotumomab [CAS 946832-34-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99254-5mg
|
MedChemexpress LLC
|
Racotumomab [CAS 946832-34-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99340-1mg
|
MedChemexpress LLC
|
Sotrovimab [CAS 2423014-07-5]
|
|
COVID-19-anti-virus
|
|
|
HY-P99340-10mg
|
MedChemexpress LLC
|
Sotrovimab [CAS 2423014-07-5]
|
|
COVID-19-anti-virus
|
|
|
HY-P99340-5mg
|
MedChemexpress LLC
|
Sotrovimab [CAS 2423014-07-5]
|
|
COVID-19-anti-virus
|
|
|
HY-P99055-1mg
|
MedChemexpress LLC
|
Urelumab [CAS 934823-49-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99055-5mg
|
MedChemexpress LLC
|
Urelumab [CAS 934823-49-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99382-1mg
|
MedChemexpress LLC
|
Vopratelimab [CAS 2039148-04-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99382-10mg
|
MedChemexpress LLC
|
Vopratelimab [CAS 2039148-04-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99382-5mg
|
MedChemexpress LLC
|
Vopratelimab [CAS 2039148-04-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-109714-100mg
|
MedChemexpress LLC
|
3,4-Benzocoumarin [CAS 2005-10-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-109714-50mg
|
MedChemexpress LLC
|
3,4-Benzocoumarin [CAS 2005-10-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99278-1mg
|
MedChemexpress LLC
|
AdecatuMu mab [CAS 503605-66-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99278-10mg
|
MedChemexpress LLC
|
AdecatuMu mab [CAS 503605-66-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99278-5mg
|
MedChemexpress LLC
|
AdecatuMu mab [CAS 503605-66-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99423-1mg
|
MedChemexpress LLC
|
Adintrevimab [CAS 2516243-54-0]
|
|
COVID-19-anti-virus
|
|
|
HY-P99423-10mg
|
MedChemexpress LLC
|
Adintrevimab [CAS 2516243-54-0]
|
|
COVID-19-anti-virus
|
|
|
HY-P99423-5mg
|
MedChemexpress LLC
|
Adintrevimab [CAS 2516243-54-0]
|
|
COVID-19-anti-virus
|
|
